|
Medicare confirms reimbursement, unlocking nationwide access to non-contrast ventilation–perfusion imaging from routine chest CT
LOS ANGELES, Sept. 4, 2025 /PRNewswire/ -- 4DMedical, a leader in advanced respiratory imaging, today announces U.S. Food and Drug Administration (FDA) 510(k) clearance for CT:VQ™, the world's first and only non-contrast, ventilation–perfusion (VQ) imaging solution. In parallel, the U.S. Centers for Medicare & Medicaid Services (CMS) has confirmed reimbursement for CT:VQ under Category III CPT codes; this payment is in addition to existing reimbursement for the underlying chest CT.
CT:VQ converts standard, non–contrast chest CTs into quantitative, lobar ventilation (V) and perfusion (Q) maps. Delivered as software–as–a–service, it integrates directly with routine radiology workflows (DICOM-based, PACS reporting) and leverages the U.S. installed base of approximately 14,500 CT scanners, bringing functional lung imaging to sites without nuclear medicine capacity.
"CT:VQ gives clinicians all the contrast—and none of the injections," said Andreas Fouras, PhD, founder and CEO of 4DMedical. "With FDA clearance and Medicare payment in place, any hospital with a CT scanner can turn a routine chest CT into a high–resolution ventilation–perfusion study in minutes, without new hardware or workflow complexity. The word 'breakthrough' is overused, but we believe the unprecedented capabilities of CT:VQ qualify for that description."
CT:VQ transforms a routine non-contrast chest CT into a reimbursable V/Q study, eliminating the need for new hardware. Patients skip injections and complete the entire process in a single CT appointment. Radiologists then receive high-resolution, quantitative V/Q maps directly in PACS. This allows pulmonologists to gain actionable information for PE workups, CTEPH assessment, COPD phenotyping, BLVR planning, and ongoing monitoring. Since CT:VQ operates on existing scanners, hospitals and imaging centers, including those without nuclear medicine, the technology can be implemented to immediately expand access to community and rural patients.
More than one million nuclear V/Q scans are performed annually in the U.S. 4DMedical's clinical validation for CT:VQ included quantitative performance testing against SPECT, expert reader studies, and real–world cases across multiple lung conditions. Early U.S. clinical partners have included Stanford University and Brooke Army Medical Center, with the later presenting initial findings at the recent 2025 American Thoracic Society meeting.
About 4DMedical
4DMedical Limited (ASX:4DX) is a global medical technology company transforming respiratory care through advanced imaging and artificial intelligence. Its patented XV Technology® powers the FDA-cleared XV LVAS®, CT LVAS™, and CT:VQ™, which deliver quantitative ventilation and perfusion analysis from non-contrast chest CT scans.
Delivered as secure, cloud-based Software-as-a-Service, 4DMedical's solutions integrate seamlessly with existing hospital systems, improving physician productivity and enabling more personalized care.
Following its 2023 acquisition of Imbio, 4DMedical delivers the most comprehensive cardiopulmonary analysis portfolio, spanning ventilation, perfusion, and parenchymal assessment on a single, cloud-delivered platform.
Learn more at www.4dmedical.com
Photo - https://mma.prnasia.com/media2/2764429/4DMedical_CT_VQ_Non_Contrast_Lung_Ventilation_Perfusion.jpg?p=medium600
Logo - https://mma.prnasia.com/media2/2730645/4DMedical_Logo.jpg?p=medium600
Medicare confirms reimbursement, unlocking nationwide access to non-contrast ventilation–perfusion imaging from routine chest CT
LOS ANGELES, Sept. 4, 2025 /PRNewswire/ -- 4DMedical, a leader in advanced respiratory imaging, today announces U.S. Food and Drug Administration (FDA) 510(k) clearance for CT:VQ™, the world's first and only non-contrast, ventilation–perfusion (VQ) imaging solution. In parallel, the U.S. Centers for Medicare & Medicaid Services (CMS) has confirmed reimbursement for CT:VQ under Category III CPT codes; this payment is in addition to existing reimbursement for the underlying chest CT.
CT:VQ converts standard, non–contrast chest CTs into quantitative, lobar ventilation (V) and perfusion (Q) maps. Delivered as software–as–a–service, it integrates directly with routine radiology workflows (DICOM-based, PACS reporting) and leverages the U.S. installed base of approximately 14,500 CT scanners, bringing functional lung imaging to sites without nuclear medicine capacity.
"CT:VQ gives clinicians all the contrast—and none of the injections," said Andreas Fouras, PhD, founder and CEO of 4DMedical. "With FDA clearance and Medicare payment in place, any hospital with a CT scanner can turn a routine chest CT into a high–resolution ventilation–perfusion study in minutes, without new hardware or workflow complexity. The word 'breakthrough' is overused, but we believe the unprecedented capabilities of CT:VQ qualify for that description."
CT:VQ transforms a routine non-contrast chest CT into a reimbursable V/Q study, eliminating the need for new hardware. Patients skip injections and complete the entire process in a single CT appointment. Radiologists then receive high-resolution, quantitative V/Q maps directly in PACS. This allows pulmonologists to gain actionable information for PE workups, CTEPH assessment, COPD phenotyping, BLVR planning, and ongoing monitoring. Since CT:VQ operates on existing scanners, hospitals and imaging centers, including those without nuclear medicine, the technology can be implemented to immediately expand access to community and rural patients.
More than one million nuclear V/Q scans are performed annually in the U.S. 4DMedical's clinical validation for CT:VQ included quantitative performance testing against SPECT, expert reader studies, and real–world cases across multiple lung conditions. Early U.S. clinical partners have included Stanford University and Brooke Army Medical Center, with the later presenting initial findings at the recent 2025 American Thoracic Society meeting.
About 4DMedical
4DMedical Limited (ASX:4DX) is a global medical technology company transforming respiratory care through advanced imaging and artificial intelligence. Its patented XV Technology® powers the FDA-cleared XV LVAS®, CT LVAS™, and CT:VQ™, which deliver quantitative ventilation and perfusion analysis from non-contrast chest CT scans.
Delivered as secure, cloud-based Software-as-a-Service, 4DMedical's solutions integrate seamlessly with existing hospital systems, improving physician productivity and enabling more personalized care.
Following its 2023 acquisition of Imbio, 4DMedical delivers the most comprehensive cardiopulmonary analysis portfolio, spanning ventilation, perfusion, and parenchymal assessment on a single, cloud-delivered platform.
Learn more at www.4dmedical.com
Photo - https://mma.prnasia.com/media2/2764429/4DMedical_CT_VQ_Non_Contrast_Lung_Ventilation_Perfusion.jpg?p=medium600
Logo - https://mma.prnasia.com/media2/2730645/4DMedical_Logo.jpg?p=medium600
** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **
4DMedical's CT:VQ™ receives FDA 510(k) clearance; First-and-only CT-based VQ technology
LOS ANGELES, May 26, 2026 /PRNewswire/ -- Vastnaut, a pioneering wearable robotics startup, today announced the successful conclusion of its three-day Demo Day in Beverly Hills, Los Angeles (May 21-23). In an unprecedented move for the consumer exoskeleton category, Vastnaut broke away from usual crowdfunding practices by inviting outdoor explorers, everyday users, and passersby to physically test Vastnaut One—the world's first AI-powered 4x4 exoskeleton—while its crowdfunding campaign is still actively running.
Building trust through genuine transparency
For early-stage hardware startups, the crowdfunding phase is often plagued by polished videos and exaggerated spec sheets that overpromise and underdeliver, leading to a growing gap in consumer trust. Vastnaut chose to tackle this head-on. The Los Angeles event was designed with one clear goal: genuine transparency. Rather than asking backers to blindly trust digital promises, Vastnaut brought the physical product directly to the community, proving that their breakthrough wearable technology is ready for the real world.
"It doesn't feel like a machine": what early adopters are actually saying
During the event, attendees were invited to walk up and down flights of stairs, perform deep crouches, and strap on heavy hiking backpacks to experience Vastnaut One's active assistance and load relief firsthand.
"It honestly feels like my own legs just got a massive upgrade," said Alex T., an amateur landscape photographer. "Since it's helping out my hips and knees at the same time, it doesn't feel like you're wearing a machine. It just moves right with you, whether you're bending down for a shot or taking the stairs."
Other attendees tested the system against typical exoskeleton pain points. "I actually brought my own 60-liter pack just to see if the frame would get in the way," noted Sarah M., an avid hiker and early backer. "It totally cleared my gear without bumping into anything. And the moment I hit the stairs, it felt like the weight of the bag just vanished. It's pretty incredible."
Weighing just 2.7 kg thanks to its 86% aerospace-grade carbon fiber construction, Vastnaut One demonstrated its ability to effectively reduce knee impact by up to 35% and uphill effort by 30% during the live demonstrations.
Los Angeles is just the beginning
"Los Angeles is just the first stop for us," the Vastnaut team stated. "We believe that building genuine trust means putting the physical product directly into our users' hands. The incredible feedback we received here proves that our industry-first End-to-End AI and 4x4 architecture truly resonate with people once they step into it. We will be taking this physical tour to other cities globally, ensuring that our community remains at the very heart of our journey."
The Vastnaut One is currently live on Kickstarter, where the campaign continues to gain momentum following the successful Los Angeles showcase.
For more information about Vastnaut One, future Demo Day stops, or to join the ongoing crowdfunding campaign, visit Vastnaut official website and its Kickstarter page.
About Vastnaut
Vastnaut is a wearable robotics company founded by engineers from leading consumer hardware brands such as DJI and EcoFlow. Combining deep expertise in robotics, biomechanics, and control systems, the company is guided by the belief that technology should extend human capability in practical, meaningful ways.
The company develops intuitive wearable robotics that build synergy between humans and the world, inspiring people to explore with amplified strength, confidence, and freedom.
Vastnaut One, the company's first product, is an AI-powered 4×4 exoskeleton built for tough terrain. Its 4×4 (4-joint × 4-motor) structure delivers powerful assistance and comprehensive multi-joint support across a variety of rugged landscapes.
** This press release is distributed by PR Newswire through automated distribution system, for which the client assumes full responsibility. **
Vastnaut Wraps Up Its First Los Angeles Demo Day, Letting Supporters Live-Test the 4x4 Exoskeleton
